onepot CORE -- an enumerated chemical space to streamline drug discovery, enabled by automated small molecule synthesis and AI

TL;DR

onepot CORE introduces an automated, AI-driven platform that enumerates and synthesizes 3.4 billion drug-like molecules, significantly streamlining early-stage drug discovery by reducing synthesis bottlenecks.

Contribution

It presents the first integrated system combining enumerated chemical space, automated synthesis, and AI planning to rapidly generate and validate diverse small molecules.

Findings

High success rate in automated synthesis workflows

Rapid validation of compounds via NMR and bioassays

Demonstrated potential for accelerated drug discovery processes

Abstract

The design-make-test-analyze cycle in early-stage drug discovery remains constrained primarily by the "make" step: small-molecule synthesis is slow, costly, and difficult to scale or automate across diverse chemotypes. Enumerated chemical spaces aim to reduce this bottleneck by predefining synthesizable regions of chemical space from available building blocks and reliable reactions, yet existing commercial spaces are still limited by long turnaround times, narrow reaction scope, and substantial manual decision-making in route selection and execution. Here we present the first version of onepot CORE, an enumerated chemical space containing 3.4B molecules and corresponding on-demand synthesis product enabled by an automated synthesis platform and an AI chemist, Phil, that designs, executes, and analyzes experiments. onepot CORE is constructed by (i) selecting a reaction set commonly used in medicinal chemistry, (ii) sourcing and curating building blocks from supplier catalogs, (iii) enumerating candidate products, and (iv) applying ML-based feasibility assessment to prioritize compounds for robust execution. In the current release, the space is supported by seven reactions. We describe an end-to-end workflow - from route selection and automated liquid handling through workup and purification. We further report validation across operational metrics (success rate, timelines, purity, and identity), including NMR confirmation for a representative set of synthesized compounds and assay suitability demonstrated using a series of DPP4 inhibitors. Collectively, onepot CORE illustrates a path toward faster, more reliable access to diverse small molecules, supporting accelerated discovery in pharmaceuticals and beyond.